Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MLNR | O43193 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422848 | 0.88 | MCHR1 (0.43) | MCHR1ACHEHRH3SLC6A4MELK | |
| SCHEMBL5453442 | 0.87 | MCHR1 (0.45) | MCHR1ACHETHRATHRBMLNR | |
| SCHEMBL5431961 | 0.86 | MCHR1 (0.44) | MCHR1ACHEHRH3SLC6A4MELK | |
| SCHEMBL5418562 | 0.86 | HRH3 (0.45) | MCHR1ACHEHRH3SLC6A4CTNNB1 | |
| SCHEMBL5421012 | 0.84 | MCHR1 (0.43) | MCHR1ACHEHRH3SLC6A4MELK | |
| SCHEMBL5428817 | 0.82 | MCHR1 (0.43) | MCHR1ACHEHRH3SLC6A4MELK | |
| SCHEMBL5420452 | 0.82 | ACHE (0.52) | MCHR1ACHETHRATHRB | |
| SCHEMBL5418939 | 0.82 | MCHR1 (0.54) | MCHR1ACHE | |
| SCHEMBL5423753 | 0.82 | MCHR1 (0.47) | MCHR1ACHECTNNB1WNT3A | |
| SCHEMBL5429436 | 0.81 | MCHR1 (0.43) | MCHR1ACHEHRH3SLC6A4MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20030158177-A1 | Treating or preventing obesity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158177-A1 | Treating or preventing obesity | MCHR1, MC1R, NPY1R | MCHR1 1/4885ACHE 4544/4885HRH3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.